197 related articles for article (PubMed ID: 32998700)
1. Leveraging TCGA gene expression data to build predictive models for cancer drug response.
Clayton EA; Pujol TA; McDonald JF; Qiu P
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):364. PubMed ID: 32998700
[TBL] [Abstract][Full Text] [Related]
2. Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.
Dorman SN; Baranova K; Knoll JH; Urquhart BL; Mariani G; Carcangiu ML; Rogan PK
Mol Oncol; 2016 Jan; 10(1):85-100. PubMed ID: 26372358
[TBL] [Abstract][Full Text] [Related]
3. A method of gene expression data transfer from cell lines to cancer patients for machine-learning prediction of drug efficiency.
Borisov N; Tkachev V; Suntsova M; Kovalchuk O; Zhavoronkov A; Muchnik I; Buzdin A
Cell Cycle; 2018; 17(4):486-491. PubMed ID: 29251172
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Chemosensitivity in Multiple Primary Cancer Patients Using Machine Learning.
Zhang X; Jang MI; Zheng Z; Gao A; Lin Z; Kim KY
Anticancer Res; 2021 May; 41(5):2419-2429. PubMed ID: 33952467
[TBL] [Abstract][Full Text] [Related]
5. Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Huang C; Clayton EA; Matyunina LV; McDonald LD; Benigno BB; Vannberg F; McDonald JF
Sci Rep; 2018 Nov; 8(1):16444. PubMed ID: 30401894
[TBL] [Abstract][Full Text] [Related]
6. Can Predictive Modeling Tools Identify Patients at High Risk of Prolonged Opioid Use After ACL Reconstruction?
Anderson AB; Grazal CF; Balazs GC; Potter BK; Dickens JF; Forsberg JA
Clin Orthop Relat Res; 2020 Jul; 478(7):0-1618. PubMed ID: 32282466
[TBL] [Abstract][Full Text] [Related]
7. Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction.
Chen ML; Doddi A; Royer J; Freschi L; Schito M; Ezewudo M; Kohane IS; Beam A; Farhat M
EBioMedicine; 2019 May; 43():356-369. PubMed ID: 31047860
[TBL] [Abstract][Full Text] [Related]
8. MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer.
Lee SH; Hwang HK; Lee WJ; Kang CM
Cell Oncol (Dordr); 2021 Dec; 44(6):1363-1371. PubMed ID: 34791637
[TBL] [Abstract][Full Text] [Related]
9. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
[TBL] [Abstract][Full Text] [Related]
10. The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Ata FK; Yalcin S
Anticancer Agents Med Chem; 2022; 22(2):371-377. PubMed ID: 34315389
[TBL] [Abstract][Full Text] [Related]
11. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
Tian K; Bakker E; Hussain M; Guazzelli A; Alhebshi H; Meysami P; Demonacos C; Schwartz JM; Mutti L; Krstic-Demonacos M
J Transl Med; 2018 Oct; 16(1):282. PubMed ID: 30316293
[TBL] [Abstract][Full Text] [Related]
12. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
[TBL] [Abstract][Full Text] [Related]
13. Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial.
Shen K; Qi Y; Song N; Tian C; Rice SD; Gabrin MJ; Brower SL; Symmans WF; O'Shaughnessy JA; Holmes FA; Asmar L; Pusztai L
BMC Med Genomics; 2012 Nov; 5():51. PubMed ID: 23158478
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
15. Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer.
Ma Z; Li Z; Ma Z; Zhou Z; Zhuang H; Liu C; Huang B; Zou Y; Zheng Z; Yang L; Gong Y; Huang S; Zhou Q; Zhang C; Hou B
Biomed Res Int; 2021; 2021():9949272. PubMed ID: 34660806
[TBL] [Abstract][Full Text] [Related]
16. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
17. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
Arumugam T; Ramachandran V; Fournier KF; Wang H; Marquis L; Abbruzzese JL; Gallick GE; Logsdon CD; McConkey DJ; Choi W
Cancer Res; 2009 Jul; 69(14):5820-8. PubMed ID: 19584296
[TBL] [Abstract][Full Text] [Related]
18. Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database.
Gemma A; Li C; Sugiyama Y; Matsuda K; Seike Y; Kosaihira S; Minegishi Y; Noro R; Nara M; Seike M; Yoshimura A; Shionoya A; Kawakami A; Ogawa N; Uesaka H; Kudoh S
BMC Cancer; 2006 Jun; 6():174. PubMed ID: 16813650
[TBL] [Abstract][Full Text] [Related]
19. Machine learning models predicting multidrug resistant urinary tract infections using "DsaaS".
Mancini A; Vito L; Marcelli E; Piangerelli M; De Leone R; Pucciarelli S; Merelli E
BMC Bioinformatics; 2020 Aug; 21(Suppl 10):347. PubMed ID: 32838752
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.
Oh SY; Jeong CY; Hong SC; Kim TH; Ha CY; Kim HJ; Lee GW; Hwang IG; Jang JS; Kwon HC; Kang JH
Invest New Drugs; 2011 Oct; 29(5):1066-72. PubMed ID: 20358256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
